CER-001 Atherosclerosis Regression ACS Trial
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 301 participants.
Also called NCT02484378
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 301 participants
- Sponsor
- Cerenis Therapeutics, SA
- Registry
-
NCT02484378
-
- Other papers using this trial's data
- Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Australia, Hungary, Netherlands
- Registry status
- Completed
Technical summary
Registry record NCT02484378. Randomized; quadruple masking; primary purpose treatment. Start 2015-08 (actual); primary completion 2016-11 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- CER-001 Atherosclerosis Regression ACS Trial
- Acronym
- CARAT
- Condition
- Acute Coronary Syndromes
- Intervention (Drug)
- CER-001
- Intervention (Drug)
- Placebo
- Lead sponsor
- Cerenis Therapeutics, SA
- Collaborator
- South Australian Health and Medical Research Institute
Record details
- Record id
cardio:ct-nct02484378- Content hash
68da87fbb93e14f10fd06fcea49952a886d0bd935b673bf7b172673a3ad21025